REGENXBIO Announce Orphan Drug Designation Granted to RGX-202, a Novel Gene Therapy Candidate for Duchenne
PPMD is pleased to share that REGENXBIO Inc. announced this morning that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for RGX-202, a gene therapy approach for the treatment of Duchenne muscular…Learn More
